Table 2.

Characteristics of patients with biopsy-proven CTCL SS

Patient IDDiagnosisStage at diagnosisAge at diagnosis, ySexRaceClonality on initial flow cytometric analysis
69 CTCL, SS IVA1 51 White 84% CD3+/CD26 T-cells; 82% CD4+/CD26; 75% CD7+/CD26 
76 CTCL, SS III 82 White 22% CD3+/CD4+/CD7 T-cells 
86 CTCL, SS IVA1 77 White 92% CD3+/CD4+/CD26; 22% CD3+/CD4+/CD7 
96 CTCL, SS IVA1 67 White 82% CD3+/CD26/CD2 
135 CTCL, SS IVA1 59 White 92% CD3+/CD26 
164 CTCL, SS IVA1 60 White 63% CD3+/CD4+/CD7+/CD26; 34% CD3+/CD4/CD8/CD7/CD26 
187 CTCL, SS IVA1 64 African American 60% CD3+/CD26; 50% CD3 biphasic/CD7 
224 CTCL, SS IVA1 82 White 98% CD2+/CD4+/CD5+/CD3/CD7/CD8/CD26 
227 CTCL, SS IVA1 56 White 93% CD4+/CD26 
Patient IDDiagnosisStage at diagnosisAge at diagnosis, ySexRaceClonality on initial flow cytometric analysis
69 CTCL, SS IVA1 51 White 84% CD3+/CD26 T-cells; 82% CD4+/CD26; 75% CD7+/CD26 
76 CTCL, SS III 82 White 22% CD3+/CD4+/CD7 T-cells 
86 CTCL, SS IVA1 77 White 92% CD3+/CD4+/CD26; 22% CD3+/CD4+/CD7 
96 CTCL, SS IVA1 67 White 82% CD3+/CD26/CD2 
135 CTCL, SS IVA1 59 White 92% CD3+/CD26 
164 CTCL, SS IVA1 60 White 63% CD3+/CD4+/CD7+/CD26; 34% CD3+/CD4/CD8/CD7/CD26 
187 CTCL, SS IVA1 64 African American 60% CD3+/CD26; 50% CD3 biphasic/CD7 
224 CTCL, SS IVA1 82 White 98% CD2+/CD4+/CD5+/CD3/CD7/CD8/CD26 
227 CTCL, SS IVA1 56 White 93% CD4+/CD26 
Close Modal

or Create an Account

Close Modal
Close Modal